

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>4DMedical Limited</b>
<b>ABN</b>	<b>31 161 684 831</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Andreas Fouras
<b>Date of last notice</b>	8 July 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	64,838,000 ordinary shares held by Velocimetry Consulting Pty Ltd, being an entity in which Andreas has more than 20% voting power. Thus, Andreas is deemed to have the same relevant interest in 4DX shares as Velocimetry Consulting Pty Ltd pursuant to section 608(3) of the Corporations Act 2001.
<b>Date of change</b>	15 December 2025
<b>No. of securities held prior to change</b>	<b>Direct</b> 11,277 Fully Paid Ordinary Shares  7,212,371 Unlisted Options  <b>Indirect</b> 64,838,000 Fully Paid Ordinary Shares
<b>Class</b>	Options
<b>Number acquired</b>	4,568,275 options
<b>Number disposed</b>	Nil

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Grant of options with an exercise price of \$0.8448 per Option calculated based on a 300% premium to the market value of the Company's shares based on the 30-day volume weighted average price (VWAP) in the period immediately preceding 30 June 2025.
<b>No. of securities held after change</b>	<b>Direct</b> 11,277 Fully Paid Ordinary Shares  11,780,646 Unlisted Options  <b>Indirect</b> 64,838,000 Fully Paid Ordinary Shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Options as approved at Annual General Meeting on 30 October 2025.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	There has been no change since the notice lodged on 1 September 2023.
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>4DMedical Limited</b>
<b>ABN</b>	<b>31 161 684 831</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Geraldine Bernadette McGinty
<b>Date of last notice</b>	17 January 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	15 December 2025
<b>No. of securities held prior to change</b>	177,787 ordinary shares
<b>Class</b>	Performance rights
<b>Number acquired</b>	213,464 Restricted Stock Units (performance rights)
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	129,280 Restricted Stock Units (performance rights) issued as a component of director's remuneration (valued at \$36,250 based on the 30-day-VWAP of \$0.2804 as at 1 July 2025).  84,184 Restricted Stock Units issued in lieu of base directors' fees (valued at \$41,250 based on 30-day-VWAP of \$0.49 as at 1 September 2025).

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	177,787 ordinary shares  213,464 Restricted Stock Units (performance rights) with a vesting date of 1 January 2026.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Restricted Stock Units as approved at Annual General Meeting on 30 October 2025.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>4DMedical Limited</b>
<b>ABN</b>	<b>31 161 684 831</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Livingston
<b>Date of last notice</b>	17 January 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares in which the beneficial interest is held by John Livingston Pty Ltd, an entity controlled by John Livingston (registered holder: Colonial First State Inv Ltd <4916557 JOHN A/C>); and  Ordinary shares in which the beneficial interest is held by JKEl Super Pty Ltd, an entity in which John Livingston has a voting power above 20% and thus is deemed by Section 608(3) of the Corporations Act 2001 to have the same relevant interest (registered holder: Colonial First State Inv Ltd <4916510 JKEl A/C>).
<b>Date of change</b>	15 December 2025

<b>No. of securities held prior to change</b>	<p><b>Direct</b> 636,576 unquoted options exercisable at \$0.79 expiring 17 January 2026</p> <p>60,147 fully paid ordinary shares</p> <p><b>Indirect</b> <u>Colonial First State Inv Ltd &lt;4916557 JOHN A/C&gt;</u> <u>(beneficial holder John Livingston Pty Ltd)</u> 424,008 fully paid ordinary shares</p> <p><u>Colonial First State Inv Ltd &lt;4916510 JKEL A/C</u> <u>(beneficial holder: JKEL Super Pty Ltd)</u> 1,501,344 fully paid ordinary shares</p>
<b>Class</b>	Options
<b>Number acquired</b>	247,648
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<p>129,280 options issued as component of director's remuneration (valued at \$36,250 based on the 30-day-VWAP of \$0.2804 as at 1 July 2025)</p> <p>118,368 options issued in lieu of base directors' fees (valued at \$58,000 based on the 30-day-VWAP of \$0.49 as at 1 September 2025).</p>
<b>No. of securities held after change</b>	<p><b>Direct</b> 636,576 unquoted options exercisable at \$0.79 expiring 17 January 2026</p> <p>60,147 fully paid ordinary shares</p> <p><b>Indirect</b> <u>Colonial First State Inv Ltd &lt;4916557 JOHN A/C&gt;</u> <u>(beneficial holder John Livingston Pty Ltd)</u> 424,008 fully paid ordinary shares</p> <p>247,648 unquoted options with a nil exercise price and expiry date of 30 June 2030.</p> <p><u>Colonial First State Inv Ltd &lt;4916510 JKEL A/C</u> <u>(beneficial holder: JKEL Super Pty Ltd)</u> 1,501,344 ordinary fully paid shares</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Options as approved at Annual General Meeting on 30 October 2025.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>4DMedical Limited</b>
<b>ABN</b>	<b>31 161 684 831</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Julian Bernard Kingsley Sutton
<b>Date of last notice</b>	3 March 2025

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Vinegar Hill Partners Pty Ltd (an entity controlled by Julian Sutton)
<b>Date of change</b>	15 December 2025
<b>No. of securities held prior to change</b>	<b>Direct:</b> 357,933 ordinary shares  4,266,666 unquoted options with exercise price of \$1.20 and expiry date of 15 March 2027  <b>Indirect:</b> 183,014 ordinary shares
<b>Class</b>	Options

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	323,158
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	129,280 options issued as component of director's remuneration (valued at \$36,250 based on the 30-day-VWAP of \$0.2804 as at 1 July 2025)  193,878 options issued in lieu of base directors' fees (valued at \$95,000 based on the 30-day-VWAP of \$0.49 as at 1 September 2025).
<b>No. of securities held after change</b>	<b>Direct:</b> 357,933 ordinary shares  4,266,666 unquoted options with exercise price of \$1.20 and expiry date of 15 March 2027  323,158 unquoted options with a nil exercise price and expiry date of 30 June 2030.  <b>Indirect:</b> 183,014 ordinary shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Options as approved at Annual General Meeting on 30 October 2025.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>4DMedical Limited</b>
<b>ABN</b>	<b>31 161 684 831</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ms Lilian Bianchi
<b>Date of last notice</b>	17 January 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Lemon Peel Pty Ltd as trustee for Lemon Peel Superannuation Fund: <ul style="list-style-type: none"><li>• director of Lemon Peel Pty Ltd;</li><li>• beneficiary of Lemon Peel Superannuation Fund</li></ul>
<b>Date of change</b>	15 December 2025
<b>No. of securities held prior to change</b>	290,212 ordinary shares
<b>Class</b>	Options
<b>Number acquired</b>	308,394

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	196,149 options issued as component of director's remuneration (valued at \$55,000 based on the 30-day-VWAP of \$0.2804 as at 1 July 2025)  112,245 options issued in lieu of base directors' fees (valued at \$55,000 based on the 30-day-VWAP of \$0.49 as at 1 September 2025).
<b>No. of securities held after change</b>	290,212 ordinary shares  308,394 unquoted options with a nil exercise price and expiry date of 30 June 2030.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Options as approved at Annual General Meeting on 30 October 2025.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>4DMedical Limited</b>
<b>ABN</b>	<b>31 161 684 831</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Robert Alan Figlin
<b>Date of last notice</b>	17 January 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	15 December 2025
<b>No. of securities held prior to change</b>	580,090 ordinary shares
<b>Class</b>	Performance rights
<b>Number acquired</b>	302,750 Restricted Stock Units (performance rights)
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	129,280 Restricted Stock Units (performance rights) issued as a component of director's remuneration (valued at \$36,250 based on the 30-day-VWAP of \$0.2804 as at 1 July 2025).  173,470 Restricted Stock Units issued in lieu of base directors' fees (valued at \$85,000 based on 30-day-VWAP of \$0.49 as at 1 September 2025).

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	580,090 ordinary shares  302,750 Restricted Stock Units (performance rights) with a vesting date of 1 January 2026
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Restricted Stock Units as approved at Annual General Meeting on 30 October 2025

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.